DV
Dividend Vision

SGP — SpyGlass Pharma, Inc.

SpyGlass Pharma, Inc. (SGP)

Total return is -0.8% over the past 0.5 years, 13.8 points behind SPY at 13.0%.

SpyGlass Pharma is a biopharmaceutical company developing drug delivery systems for chronic eye conditions, primarily the Bimatoprost Drug Pad-IOL System, which combines medication with intraocular lenses to reduce elevated intraocular pressure during cataract surgery, along with a separate sustained-release implant. The company does not currently distribute dividends. SpyGlass Pharma appeals to investors seeking exposure to ophthalmology and drug delivery innovation rather than current income.

SGP key facts

Asset type
Stock
Asset class
Equity
Inception date
02/06/2026
Last close
$26.20
Market cap
$669,335,808
Average volume
69700.0
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.34